Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Amgen/Novartis CGRP Inhibitor Migraine Data Underwhelm Ahead Of Phase III Apex

Executive Summary

Amgen Inc. and Novartis AG are busy shoring up the case for their CGRP inhibitor erenumab – which is in a race with three others to be the first on to the migraine market. Positive topline Phase II data with erenumab has been reported but analysts suggest they may not be as strong as those from its competitors. The four CGRP inhibitors are all in Phase III with late-stage data expected this year.


Related Content

Amgen Plugs Away On Repatha, With Hope For New Monthly Product
Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
Amgen, Novartis Trade Rights For Migraine, Alzheimer's Drugs


Related Companies